Starting July 2026, Cigna is drawing a line in the sand by discontinuing coverage for popular weight-loss medications like Wegovy and Zepbound for its employees. Citing rising expenses and available alternatives, this decision reflects a broader trend among employers weighing the financial implications of such costly treatments. It’s noteworthy that coverage for diabetes patients will continue to remain unaffected.
